NanoViricides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo (DRC) has approved the company's proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. This approval represents a significant step forward for the company's broad-spectrum antiviral candidate, which is designed to target host-cell features required by viruses, potentially offering an oral treatment option for Ebola.
According to the company, NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical testing, to its knowledge. The next steps include obtaining approvals from the DRC National Ethics Committee and regulatory agency ACOREP before initiating the study. The company noted that NV-387 Oral Gummies have already received authorization in the DRC for a Phase II mpox trial and are ready for shipment.
Management believes the oral formulation could offer significant advantages in resource-limited outbreak settings, where intravenous treatments can be difficult to deploy and scale. This is particularly relevant in the context of the ongoing Bundibugyo ebolavirus outbreak, which requires rapid and effective interventions. The ability to administer treatment orally could simplify logistics and increase patient access in remote areas.
NanoViricides is a clinical stage company focused on creating special purpose nanomaterials for antiviral therapy. The company's lead drug candidate is NV-387, a broad-spectrum antiviral drug that the company plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and Measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
The approval from the DRC Pillar Committee underscores the potential of NV-387 as a versatile antiviral agent. The company's platform technology is based on the TheraCour® nanomedicine technology, which it licenses from TheraCour Pharma, Inc. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of various human viral diseases.
For more details, the full press release is available at https://nnw.fm/1ewVT. Additional information about NanoViricides can be found at www.nanoviricides.com. The latest news and updates relating to NNVC are available in the company's newsroom at https://nnw.fm/NNVC.
